Media stories about Fonar (NASDAQ:FONR) have trended positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fonar earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 45.3094860802989 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Fonar (FONR) traded down $0.10 during trading on Wednesday, reaching $25.30. 16,604 shares of the company traded hands, compared to its average volume of 30,917. Fonar has a one year low of $17.20 and a one year high of $33.90. The stock has a market cap of $159.07, a price-to-earnings ratio of 8.72 and a beta of 2.36.
In other news, Director Robert J. Janoff sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $25.73, for a total transaction of $25,730.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.33% of the company’s stock.
Fonar Corporation (Fonar) is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilizes MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions and injuries. The Company operates its business through two segments: Medical Equipment segment, and Physician Management and Diagnostic Services segment.
Receive News & Ratings for Fonar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fonar and related companies with MarketBeat.com's FREE daily email newsletter.